Takeda Pharmaceutical Co. (TAK)

Last Price: 16.87 (2021-05-07)

Company Description

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $30.20B
Net Income (Most Recent Fiscal Year) $407.02M
PE Ratio (Current Year Earnings Estimate) 8.56
PE Ratio (Trailing 12 Months) 9.75
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 1.78
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.19
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 4.88
Pre-Tax Margin (Trailing 12 Months) 5.62%
Net Margin (Trailing 12 Months) 5.69%
Return on Equity (Trailing 12 Months) 12.04%
Return on Assets (Trailing 12 Months) 4.50%
Current Ratio (Most Recent Fiscal Quarter) 1.45
Quick Ratio (Most Recent Fiscal Quarter) 1.04
Debt to Common Equity (Most Recent Fiscal Quarter) 0.96
Inventory Turnover (Trailing 12 Months) 1.31
Book Value per Share (Most Recent Fiscal Quarter) $13.80
Earnings per Share (Most Recent Fiscal Quarter) $0.56
Earnings per Share (Most Recent Fiscal Year) $1.78
Diluted Earnings per Share (Trailing 12 Months) $0.55
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Common Shares Outstanding 3.16B
Free Float --
Market Capitalization $53.24B
Average Volume (Last 20 Days) 2.15M
Beta (Past 60 Months) 1.05
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 2.86%
Annual Dividend (Based on Last Quarter) $0.72
Dividend Yield (Based on Last Quarter) 4.27%